RT Journal Article
SR Electronic
T1 High levels of common cold coronavirus antibodies in convalescent plasma are associated with improved survival in COVID-19 patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.08.21252775
DO 10.1101/2021.03.08.21252775
A1 Greenbaum, Uri
A1 Klein, Kimberly
A1 Martinez, Fernando
A1 Song, Juhee
A1 Thall, Peter F.
A1 Ramdial, Jeremy L.
A1 Knape, Cristina
A1 Aung, Fleur M.
A1 Scroggins, Jamie
A1 Knopfelmacher, Adriana
A1 Mulanovich, Victor
A1 Borjan, Jovan
A1 Adachi, Javier
A1 Muthu, Mayoora
A1 Leung, Cerena
A1 Medina, Mayrin Correa
A1 Champlin, Richard
A1 Olson, Amanda
A1 Alousi, Amin
A1 Rezvani, Katayoun
A1 Shpall, Elizabeth J.
YR 2021
UL http://medrxiv.org/content/early/2021/03/10/2021.03.08.21252775.abstract
AB Background COVID-19 Convalescent plasma (CCP) is safe and effective, particularly if given at an early stage of the disease. Our study aimed to identify an association between survival and specific antibodies found in CCP.Patients and Methods Patients ≥18 years of age who were hospitalized with moderate to severe COVID-19 infection and received CCP at the MD Anderson Cancer Center between 4/30/2020 and 8/20/2020 were included in the study. We quantified the levels of anti-SARS-CoV-2 antibodies, as well as antibodies against antigens of other coronavirus strains, in the CCP units and compared antibody levels with patient outcomes. For each antibody, a Bayesian exponential survival time regression model including prognostic variables was fit, and the posterior probability of a beneficial effect (PBE) of higher antibody level on survival time was computed.Results CCP was administered to 44 cancer patients. The median age was 60 years (range 37-84) and 19 (43%) were female. Twelve patients (27%) died of COVID-19-related complications. Higher levels of two non-SARS-CoV-2-specific antibodies, anti-HCoV-OC43 spike IgG and anti-HCoV-HKU1 spike IgG, had PBE = 1.00, and 4 SARS-CoV-2-specific antibodies had PBEs between 0.90 and 0.95. Other factors associated with better survival were shorter time to CCP administration, younger age, and female sex.Conclusions Common cold coronavirus spike IgG antibodies anti-HCoV-OC43 and anti-HCoV-HKU1 may target a common domain for SARS-CoV-2 and other coronaviruses. They provide a promising therapeutic target for monoclonal antibody production.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04338360Funding StatementThis study was part of a nationwide expanded access protocol for the administration of CCP for the treatment of COVID-19 and was funded in part with Federal funds from the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority under Contract No. 75A50120C00096. The funding party did not participate in this study design collection analysis interpretation of the data or in the writing of the report and the decision to submit the paper for publication. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the University of Texas MD Anderson Cancer Center institutional review board (study ID 2020-0444, external study ID 20-003312) as part of the nationwide expanded access protocol approved by the Mayo Clinic Institutional Review Board, in accordance with 45 CFR 46.103(e), on April 4, 2020. National Clinical Trial (NCT) Identification Number: 04338360.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPlease contact the corresponding author for study dataset availability